Pharma share prices: are we there yet?

The final two weeks of June and the start of the third quarter reveal an uptick that many will find hard to ignore, and on top of this comes increased talk of takeovers. As much of the industry departs for the summer shutdown some will say the bottom has been hit at last, though given the extent of investors’ losses it would be premature to expect a bull market to come roaring back just yet.